Adjuvant nivolumab improves survival after radical cystectomy
Sign Up to like & getrecommendations! Published in 2021 at "Nature Reviews Urology"
DOI: 10.1038/s41585-021-00493-x
Abstract: A phase III randomized, controlled trial has investigated the role of adjuvant treatment in high-risk muscle-invasive urothelial carcinoma after radical surgery. Patients with muscleinvasive cancer who had undergone radical cystectomy received nivolumab (240 mg intravenously;… read more here.
Keywords: group; improves survival; adjuvant nivolumab; radical cystectomy ... See more keywords
Adjuvant nivolumab therapy may not improve disease‐free survival in resected acral lentiginous melanoma patients: A retrospective case series
Sign Up to like & getrecommendations! Published in 2022 at "Dermatologic Therapy"
DOI: 10.1111/dth.15817
Abstract: Adjuvant nivolumab therapy has been reported to improve the survival of melanoma patients. Acral lentiginous melanoma (ALM) has been reported to be less likely to respond to immune checkpoint inhibitors (ICIs) than other subtypes. However,… read more here.
Keywords: nivolumab therapy; melanoma; survival; therapy ... See more keywords
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-005684
Abstract: Background Adjuvant therapy for high-risk resected melanoma with programmed cell-death 1 blockade results in a median relapse-free survival (RFS) of 5 years. The addition of low dose ipilimumab (IPI) to a regimen of adjuvant nivolumab… read more here.
Keywords: high risk; resected melanoma; adjuvant nivolumab; ipi nivo ... See more keywords
Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis
Sign Up to like & getrecommendations! Published in 2021 at "BMC Cancer"
DOI: 10.1186/s12885-020-07538-1
Abstract: Background Immune checkpoint inhibitors and targeted therapies are approved for adjuvant treatment of patients with resected melanoma; however, they have not been compared in randomized controlled trials (RCTs). We compared the efficacy and safety of… read more here.
Keywords: safety adjuvant; efficacy safety; resected melanoma; adjuvant nivolumab ... See more keywords